Compounds for treating proliferative disorders

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9156783
APP PUB NO 20150025042A1
SERIAL NO

14108162

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed are compounds of formulae (I), (III), (IV), (VII), (X), (XI), (XII), (XIII) and (XIV), wherein the variables are as defined in the claims, and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • SYNTA PHARMACEUTICALS CORP.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chen, Shoujun Bedford, US 114 1516
Demko, Zachary San Francisco, US 146 7766
Koya, Keizo Chestnut Hill, US 97 1161
Sun, Lijun Harvard, US 213 2596

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 13, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00